

Sepsis

B. Taylor Thompson M.D.

Professor of Medicine,
Harvard Medical School

Outline

- Sepsis Defined
- New mechanistic insights
- Sepsis subphenotypes

Sepsis

- Sepsis is a term derived from the ancient Greek for rotten flesh and putrefaction.
- 1680s: Leeuwenhoek's observed "animalcules" (bacteria)
- 200 years passed before bacteria were linked to infection (Koch, Pasteur, Semmelweis, and Lister).
- 1914: Schottmueller concluded that pathogenic germs in the bloodstream caused systemic symptoms and signs
- 1975: Systemic release of cytokines and activation of white blood cells and coagulation even in the absence of whole bacteria caused sepsis

Sepsis

- Third most common cause of death world wide
- Over 1 million cases of sepsis in the US with a mortality of 10 - 40%
- Major sites of infection leading to sepsis:
 - Lung
 - Abdomen
 - Urinary tract
 - Skin and Soft Tissues
 - Central nervous system
(30% unknown source)

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour, MD, MSc; Manu Shankar-Hari, MSc, MD, FFICM; Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD; Jean-Daniel Chiche, MD, PhD; Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall, MD; Greg S. Martin, MD, MSc; Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vincent, MD, PhD; Derek C. Angus, MD, MPH

Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

Developing a New Definition and Assessing New Clinical Criteria for Septic Shock

For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Literature review, Delphi,
3 Cohorts ~3.2 million pts

Manu Shankar-Hari, MD, MSc; Gary S. Phillips, MAS; Mitchell L. Levy, MD; Christopher W. Seymour, MD, MSc; Vincent X. Liu, MD, MSc; Clifford S. Deutschman, MD; Derek C. Angus, MD, MPH; Gordon D. Rubenfeld, MD, MSc; Mervyn Singer, MD, FRCP; for the Sepsis Definitions Task Force

Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

Assessment of Clinical Criteria for Sepsis

For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Assess predictive validity
in ~1.3 million patients

Christopher W. Seymour, MD, MSc; Vincent X. Liu, MD, MSc; Theodore J. Iwashyna, MD, PhD; Frank M. Brunkhorst, MD; Thomas D. Rea, MD, MPH; André Scherag, PhD; Gordon Rubenfeld, MD, MSc; Jeremy M. Kahn, MD, MSc; Manu Shankar-Hari, MD, MSc; Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Gabriel J. Escobar, MD; Derek C. Angus, MD, MPH

SEPSIS-3, ICU Definition:

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection

Organ dysfunction is measured by abnormal laboratory values, blood pressure, and mental status. The Sequential Organ Failure Assessment (SOFA) score is used to grade severity of organ dysfunction on a 0-4 point scale for each organ system

A 2 point change in total SOFA from infection is associated with a 10% mortality risk in a general hospital population.

SOFA Score

System	Score				
	0	1	2	3	4
Respiration					
Pao ₂ /Fio ₂ , mm Hg (kPa)	≥400 (53.3)	<400 (53.3)	<300 (40)	<200 (26.7) with respiratory support	<100 (13.3) with respiratory support
Coagulation					
Platelets, ×10 ³ /μL	≥150	<150	<100	<50	<20
Liver					
Bilirubin, mg/dL (μmol/L)	<1.2 (20)	1.2-1.9 (20-32)	2.0-5.9 (33-101)	6.0-11.9 (102-204)	>12.0 (204)
Cardiovascular	MAP ≥70 mm Hg	MAP <70 mm Hg	Dopamine <5 or dobutamine (any dose) ^b	Dopamine 5.1-15 or epinephrine ≤0.1 or norepinephrine ≤0.1 ^b	Dopamine >15 or epinephrine >0.1 or norepinephrine >0.1 ^b
Central nervous system					
Glasgow Coma Scale score ^c	15	13-14	10-12	6-9	<6
Renal					
Creatinine, mg/dL (μmol/L)	<1.2 (110)	1.2-1.9 (110-170)	2.0-3.4 (171-299)	3.5-4.9 (300-440)	>5.0 (440)
Urine output, mL/d				<500	<200

Sepsis Surveillance Using Adult Sepsis Events Simplified eSOFA Criteria Versus Sepsis-3 Sequential Organ Failure Assessment Criteria*

Chanu Rhee, MD, MPH^{1,2}; Zilu Zhang, MS¹; Sameer S. Kadri, MD, MS³; David J. Murphy, MD, PhD⁴;
Greg S. Martin, MD, MSc⁴; Elizabeth Overton, MS⁴; Christopher W. Seymour, MD, MSc⁵;
Derek C. Angus, MD, MPH⁵; Raymund Dantes, MD, MPH^{6,7}; Lauren Epstein, MD, MS⁶;
David Fram, BA⁸; Richard Schaaf, SM⁸; Rui Wang, PhD¹; Michael Klompas, MD, MPH^{1,2};
for the CDC Prevention Epicenters Program

TABLE 1. The Sequential Organ Failure Assessment Score and eSOFA Criteria

Organ System	Sequential Organ Failure Assessment Score	eSOFA
Cardiovascular ^a	<ol style="list-style-type: none"> 1) Mean arterial pressure < 70 mm Hg 2) Dopamine ≤ 5 µg/kg/min or dobutamine (any dose) 3) Dopamine > 5 or epinephrine ≤ 0.1 or norepinephrine ≤ 0.1 µg/kg/min 4) Dopamine > 15 or epinephrine > 0.1 or norepinephrine > 0.1 µg/kg/min 	Vasopressor initiation
Pulmonary	<ol style="list-style-type: none"> 1) Pao₂/Fio₂ 300–399 2) Pao₂/Fio₂ 200–299 3) Pao₂/Fio₂ 100–199 and ventilated 4) Pao₂/Fio₂ ratio < 100 and ventilated 	Mechanical ventilation initiation (> 1 calendar day required between vent episodes)
Renal ^b	<ol style="list-style-type: none"> 1) Creatinine 1.2–1.9 mg/dL 2) Creatinine 2.0–3.4 mg/dL 3) Creatinine 3.5–4.9 mg/dL or UOP < 500 cc/d 4) Creatinine > 5.0 mg/dL or UOP < 200 cc/d 	2× Creatinine or ↓ ≥ 50% of eGFR relative to baseline (excluding patients with end-stage renal disease)
Hepatic	<ol style="list-style-type: none"> 1) Bilirubin 1.2–1.9 mg/dL 2) Bilirubin 2.0–5.9 mg/dL 3) Bilirubin 6.0–11.9 mg/dL 4) Bilirubin > 12.0 mg/dL 	Bilirubin ≥ 2.0 mg/dL and ↑2× from baseline
Coagulation	<ol style="list-style-type: none"> 1) Platelets 100–149 cells/µL 2) Platelets 50–99 cells/µL 3) Platelets 20–49 cells/µL 4) Platelets < 20 cells/µL 	Platelet count < 100 cells/µL and ↓ ≥ 50% from baseline (baseline must be ≥ 100 cells/µL)
Neuro	<ol style="list-style-type: none"> 1) Glasgow Coma Scale score 13–14 2) Glasgow Coma Scale score 10–12 3) Glasgow Coma Scale score 6–9 4) Glasgow Coma Scale score < 6 	“None” Perfusion dysfunction: lactate ≥ 2.0 mmol/L

SEPSIS-3: Septic Shock

Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality

Septic Shock Definition:

Persisting hypotension requiring vasopressors to maintain a mean arterial pressure of > 65 mmHg and having a serum lactate level > 2 mmol/L despite “adequate” (NOS) volume resuscitation.

Hospital mortality $> 40\%$.

Singer JAMA 2016

Outline

- Sepsis Defined
- New mechanistic insights
- Sepsis subphenotypes

Innate Immune Response Triggered by Interactions with Pattern Recognition Receptors:





Toll-like receptors


Receptor for advanced glycation end products

Nucleotide-binding oligomerization domain-like receptors

C-type lectin receptors

Retinoic acid-inducible gene-1-like receptors


Examples of Pathogen-Associated Molecular Patterns (PAMPs)	
Bacteria 	Flagellin, LPS, Peptidoglycans, Lipoteichoic acid, Formyl peptides, DNA, Unmethylated CpG motifs, Glycolipids, Lipoproteins
Virus 	Envelope glycoprotein, ssRNA, dsRNA, Unmethylated CpG motifs
Fungus 	β -glucans, Mannoproteins, Unmethylated CpG motifs, Phospholipomannan
Parasite 	Profilin, Glycolipids, DNA



Host-pathogen interaction

Pathogen factors
Load
Virulence
Pathogen-associated molecular patterns


Damage-associated molecular patterns



Antiinflammatory response

Immunosuppression with enhanced susceptibility to secondary infections

Higher Circulating Mitochondrial DNA in Fatal Sepsis



Sepsis and Organ Dysfunction

Coma or Encephalopathy


- Altered consciousness, confusion, psychosis
- EEG shows diffuse slowing
- Brain structurally normal

ARDS

- Inflammation, vascular leak, intravascular coagulation

Shock

- Vascular smooth muscle cells become hyperpolarized due to changes in potassium conductance
- Increased endogenous vasodilators



Heart Failure


- Heart weakens and dilates due to circulating factors
- Markers of heart muscle death circulate in the blood but the heart muscles largely appear to be normal histologically

Kidney Failure

- Urine flow is reduced and medicines to increase flow (diuretics) no longer work
- Epithelial cells are present in the urine suggesting injury though renal histology is largely normal
- Vast majority with failed kidneys requiring dialysis recover

Survival in Critical Illness Is Associated with Early Activation of Mitochondrial Biogenesis



Jane E. Carré¹, Jean-Christophe Orban^{1,2}, Lorenza Re^{1,3}, Karen Felsmann⁴, Wiebke Iffert⁴, Michael Bauer⁵, Hagir B. Suliman⁶, Claude A. Piantadosi⁶, Terry M. Mayhew⁷, Patrick Breen¹, Martin Stotz¹, and Mervyn Singer¹



Survival in Critical Illness Is Associated with Early Activation of Mitochondrial Biogenesis

2010

Jane E. Carré¹, Jean-Christophe Orban^{1,2}, Lorenza Re^{1,3}, Karen Felsmann⁴, Wiebke Iffert⁴, Michael Bauer⁵, Hagir B. Suliman⁶, Claude A. Piantadosi⁶, Terry M. Mayhew⁷, Patrick Breen¹, Martin Stotz¹, and Mervyn Singer¹



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812


FEBRUARY 10, 2005

VOL. 352 NO. 6

Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress

Patient No.	Age <i>yr</i>	Sex	Race or Ethnic Origin	Coronary Risk Factors	Emotional Stressor	Time after Symptom Onset† <i>hr</i>
1	62	F	B	HTN, smoking	Mother's death	12
2	63	F	AA	HTN, Chol	Car accident	1
3	48	F	W	HTN, Chol, smoking	Surprise reunion	4
4	60	F	W	HTN	Surprise party	2
5	66	F	W	HTN, FH	Father's death	5
6	77	F	W	HTN, FH	Husband's death	6
7	52	F	W	Smoking	Friend's death	2

Antibiotics and Sepsis; necessary but not sufficient for survival



+ Kreger AJM 1980; Simon Crit Care Clin 2000

* Pittet AJRCCM 1996; Opal CCM 1997

Immune Modulation for Severe Sepsis has Largely Failed

No Benefit or Harm in >100 studies

- Anti-LPS (Polyclonal Ab, HA-1A, E5)
- Anti-TNF or IL-1 strategies
- IVIG, Interferon gamma, GCSF
- Growth hormone
- Soluble PLA₂, elastase, and PAF Inhibitors
- Heparin, antithrombin
- Ibuprofen
- APC for lower risk severe sepsis
- Tissue factor pathway inhibitor (Opal ESICEM 2009)
- Phospholipid emulsion (Dellinger CCM 2009)
- TLR-4 antagonist (Tidswell CCM 2010, Opal, 2012)
- APC for persistent septic shock (Ranieri & Thompson, 2012)


For sepsis, the drugs don't work

“A deeper understanding of the processes leading to sepsis is necessary before we can design an effective suite of interventions.”


The Lancet Infectious Disease; Feb 2012

The response to infection differs between individuals. Up to 6 different sepsis responses (or sepsis subtypes) to infection have been reported

Six subphenotypes in septic shock: Latent class analysis of the PROWESS Shock study



Bengt Gårdlund ^{a,*}, Natalia O. Dmitrieva ^b, Carl F. Pieper ^c, Simon Finfer ^d,
John C. Marshall ^e, B. Taylor Thompson ^f





Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study

Brendon P Scicluna, Lonneke A van Vught, Aeilko H Zwinderman, Maryse A Wiewel, Emma E Davenport, Katie L Burnham, Peter Nürnberg, Marcus J Schultz, Janneke Horn, Olaf L Cremer, Marc J Bonten, Charles J Hinds, Hector R Wong, Julian C Knight, Tom van der Poll, on behalf of the MARS consortium*

Unsupervised consensus clustering and machine learning of the blood transcriptome in patients with sepsis from severe CAP

Pattern recognition receptor and cytokine signalling



Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis

Christopher W. Seymour, MD, MSc; Jason N. Kennedy, MS; Shu Wang, MS; Chung-Chou H. Chang, PhD; Corrine F. Elliott, MS; Zhongying Xu, MS; Scott Berry, PhD; Gilles Clermont, MD, MSc; Gregory Cooper, MD, PhD; Hernando Gomez, MD, MPH; David T. Huang, MD, MPH; John A. Kellum, MD, FACP, MCCM; Qi Mi, PhD; Steven M. Opal, MD; Victor Talisa, MS; Tom van der Poll, MD, PhD; Shyam Visweswaran, MD, PhD; Yoram Vodovotz, PhD; Jeremy C. Weiss, MD, PhD; Donald M. Yealy, MD, FACEP; Sachin Yende, MD, MS; Derek C. Angus, MD, MPH

Retrospective analysis of four large datasets (n=16-43k) and 4 RCTs (n=)4737

Machine learning and unsupervised clustering methods using clinical data


Four subgroups of sepsis = best fit

Mortality


α (33%): most common, lowest vasopressors	5%
β (27%): older, more chronic illness and renal dysfunction	13%
γ (27%): more inflammation and pulmonary dysfunction	24%
δ (13%): more liver dysfunction and septic shock	40%

Results of 10,000 simulated trials with different subtype distributions (more α or δ)


A Baseline data



B Varying the frequency of the α phenotype in simulation



C Varying the frequency of the δ phenotype in simulation



Transcriptomic Signatures in Sepsis and a Differential Response to Steroids: From the VANISH Randomized Trial

 David B Antcliffe ; Katie L Burnham , Farah Al-Beidh , Shalini Santhakumaran , Stephen J Brett , Charles J. Hinds , Deborah Ashby , 
Julian C Knight , and Anthony C Gordon ;

Patients with the immunocompetent Sepsis Response Type 2 subtype who were treated with corticosteroids had poorer survival than those given placebo

- **OR for death = 7.9 (1.6-39.9); interaction p = 0.02**

Sepsis Subtypes

As for Type 1 and Type 2 diabetics, we will have a different understanding of and will be making different treatment decisions for patients with “Type 1 sepsis, Type 2 sepsis, etc. etc. etc.”

Summary and Conclusion

- Sepsis is a common and potentially lethal response to infection
- The release of molecules from the initial tissue injury amplify the response
- Dysregulated innate immune response has both hyper and hypo-inflammatory responses that appear to differing degrees in different subtypes
- A Systems Biology approach to understanding sepsis and multiple organ failure will need to embrace this heterogeneity and perhaps explain it

Summary and Conclusion

- Future treatments will likely be guided by a better understanding of the subtypes of immune and coagulation system dysregulation and seek to restore homeostasis (and perhaps cellular energetics)

Thank you

thompson.taylor@mgh.harvard.edu


Extra Slides


STUDY PROTOCOL

Open Access

The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial



David N. Hager^{1*} , Michael H. Hooper², Gordon R. Bernard³, Laurence W. Busse⁴, E. Wesley Ely^{5,6,7}, Alpha A. Fowler⁸, David F. Gaijeski⁹, Alex Hall^{10,11}, Jeremiah S. Hinson¹², James C. Jackson^{5,6,7,13}, Gabor D. Kelen¹², Mark Levine¹⁴, Christopher J. Lindsell¹⁵, Richard E. Malone¹⁶, Anna McGlothlin¹⁷, Richard E. Rothman¹², Kert Viele¹⁷, David W. Wright^{10,11}, Jonathan E. Sevransky⁴ and Greg S. Martin^{4,11}



SEPSIS-3 Definition of Shock

Why Vasopressors and Lactate > 2?

Variable	Hypotension after fluids	Vasopressor	Raised Lactate >2 mmol/L
Group 1	Yes	Yes	Yes
Group 2	Yes	Yes	No
Group 3	Yes	No	Yes
Group 4	No	No	Yes
Group 5	No hypotension before fluids	No	Yes
Group 6	Yes	No	No

Variables	N	Hospital mortality, N (%)
Group		
1 (referent)	8,520	3,602 (42.3)
2	3,985	1,198 (30.1)
3	223	64 (28.7)
4	3,266	839 (25.7)
5	2,696	802 (29.7)
6	150	28 (18.7)

Sepsis Surveillance Using Adult Sepsis Events Simplified eSOFA Criteria Versus Sepsis-3 Sequential Organ Failure Assessment Criteria*

Chanu Rhee, MD, MPH^{1,2}; Zilu Zhang, MS¹; Sameer S. Kadri, MD, MS³; David J. Murphy, MD, PhD⁴;
Greg S. Martin, MD, MSc⁴; Elizabeth Overton, MS⁴; Christopher W. Seymour, MD, MSc⁵;
Derek C. Angus, MD, MPH⁵; Raymund Dantes, MD, MPH^{6,7}; Lauren Epstein, MD, MS⁶;
David Fram, BA⁸; Richard Schaaf, SM⁸; Rui Wang, PhD¹; Michael Klompas, MD, MPH^{1,2};
for the CDC Prevention Epicenters Program

Critical Care Medicine 2019

